Skip to content
Research Article Open access CC BY 4.0

Potential Effect of Chloroquine in Modulating Hyperglycemia and PTEN Receptor Linked Dyslipidemia on Alloxan-induced Diabetic Mice

Imaobong C. Etti, Eno-obong A. Essang, Emmanuel O. Olorunsola

Asian Journal of Biochemistry, Genetics and Molecular Biology · pp. 62–69 · Published 7 May 2024

10.9734/ajbgmb/2024/v16i6383

Abstract

Background: Diabetes mellitus is a life-threatening disease associated with worsening of glycemic control, progressive metabolic dysfunctions and disruption of the Phosphatase and Tensin Homolog (PTEN) receptor.  Purpose: To evaluate the effect of chloroquine on blood glucose level and lipid profile of alloxan-induced diabetic mice and to observe its interaction with PTEN, a negative regulator of insulin signaling pathway. Methodology: Thirty mice were used for the experiment. A group (n = 5) was kept as healthy control while the others were pre-treated with 140 mg/kg of alloxan monohydrate in distilled water. The alloxan-induced diabetic mice were randomly divided into four groups: diabetic model control group, 60 mg/kg chloroquine, 120 mg/kg chloroquine, and 10 mg/kg glibenclamide treatment groups respectively. Treatment was done once daily for seven days and the blood glucose level was investigated acutely and then daily throughout the experimental period. A molecular docking study was also conducted to evaluate the interaction of chloroquine with PTEN using PYRX software, while an automated COBAS C 311 machine was used to analyze the lipid profile after the treatment period.  Results: Oral administration of chloroquine gradually and significantly lowered the raised blood glucose level in a time- and dose-dependent manner. A repeated study with 120 mg/kg of chloroquine revealed a decline in blood sugar from 221.5 ± 3.6 on day 1 to 85.5 ± 2.4 on day 7 in comparison to glibenclamide, whose sugar level was reduced to 75.5 ± 3.7 at the end of day 7. The docking study revealed a non-competitive inhibition with an inhibition score of -6.1 in comparison to metformin, which had a score of -4.4, and glibenclamide, which had a score of -9.0. This interaction resulted in a conformational change of the receptor, hence, enhancing glucose uptake and reducing the raised hyperglycemia. Treatment with chloroquine was also observed to reduce the total cholesterol and triglyceride levels from 162 in the model group to 144 and 141 to 116 mmol/L, respectively. The levels of low-density lipoprotein cholesterol (LDL-C) and very low-density lipoprotein (VLDL) following treatment with chloroquine were not statistically different from the non-diabetic healthy mice. These values were very similar to those obtained with glibenclamide-treated diabetic mice. Conclusion: From the results, chloroquine possesses potent antidiabetic properties and can improve dyslipidemia imposed by hyperglycemia probably owing to its inhibition of PTEN, a negative regulator of insulin resistance.

Diabetes chloroquine PTEN blood glucose level dyslipidemia polydipsia chronic metabolic disease

References (18)

  1. 1 Dyslipidemia in type 2 diabetes mellitus [DOI]
  2. 2 Pathophysiology of Diabetic Dyslipidemia [DOI]
  3. 3 Diabetes Mellitus and Its Metabolic Complications: The Role of Adipose Tissues [DOI]
  4. 4 Diabetes Mellitus: Insights from Epidemiology, Biochemistry, Risk Factors, Diagnosis, Complications and Comprehensive Management [DOI]
  5. 5 Anti-inflammatory and Antioxidant Properties of HDLs Are Impaired in Type 2 Diabetes [DOI]
  6. 6 Dyslipidemia and diabetes mellitus: Role of lipoprotein species and interrelated pathways of lipid metabolism in diabetes mellitus [DOI]
  7. 7 Treatment of dyslipidemia in patients with type 2 diabetes [DOI]
  8. 8 Chloroquine analogs as antimalarial candidates with potent in vitro and in vivo activity [DOI]
  9. 9 Low-grade inflammation in type 2 diabetes: a cross-sectional study from a Danish diabetes outpatient clinic [DOI]
  10. 10 Regulation of Insulin Synthesis and Secretion and Pancreatic Beta-Cell Dysfunction in Diabetes [DOI]
  11. 11 Immunomodulatory Effects of Hydroxychloroquine and Chloroquine in Viral Infections and Their Potential Application in Retinal Gene Therapy [DOI]
  12. 12 Oxidative stress and inflammatory markers in type 2 diabetic patients [DOI]
  13. 13 Chloroquine stimulates glucose uptake and glycogen synthase in muscle cells through activation of Akt [DOI]
  14. 14 Prevalence of dyslipidemia and associated risk factors among newly diagnosed Type-2 Diabetes Mellitus (T2DM) patients in Kushtia, Bangladesh [DOI]
  15. 15 Low dose chloroquine decreases insulin resistance in human metabolic syndrome but does not reduce carotid intima-media thickness [DOI]
  16. 16 Profiling the Antidiabetic Potential of Compounds Identified from Fractionated Extracts of Entada africana toward Glucokinase Stimulation: Computational Insight [DOI]
  17. 17 Serum Vitamin D Levels in Persons with Type 2 Diabetes Mellitus in Lagos, Nigeria [DOI]
  18. 18 Chloroquine inhibits pro-inflammatory effects of heme on macrophages and in vivo [DOI]

Cited by 2

Impact of Experimental Diabetes on Memory Performance in Mice

P. Doubran, K. E. Bégbin, Akoua Jeanne Kanga · The Journal of Bioscience and Medicine · 2026

Showing 1 of 2 known citations — external sources report more than can currently be individually listed.

Related research

Article metrics

Real usage data collected on this platform.

66

Page views

0

PDF downloads

13

Outbound clicks

2

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.